source
- FDA selects Dexcom as first participant in TEMPO digital health pilotThe U.S. Food and Drug Administration announced that Dexcom, Inc. has been chosen as the inaugural manufacturer for the Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot focused on digit…
- Mentari Therapeutics secures second $200M private placement to fund migraine program and advance reverse mergerMentari Therapeutics, a spin‑out focused on migraine treatments, announced it has arranged a second private‑placement financing of $200 million. The new capital will be used to advance its migrain…